

Cite this: *Nanoscale Adv.*, 2024, 6, 458

# Development of a protocol of isolation of nanoparticles from patients' broncho-alveolar lavages for their *in vitro* toxicity assessment

Kévin Bernal,<sup>a</sup> Ozge Kose,<sup>a</sup> Lara Leclerc,<sup>a</sup> Jean-Michel Vergnon,<sup>bc</sup>  
Jérémy Pourchez<sup>ib</sup><sup>a</sup> and Valérie Forest<sup>ib</sup><sup>\*a</sup>

To investigate potential correlations between human exposure to inhaled particles and pathological effects, the biological monitoring of nanoparticles in broncho-alveolar lavages (BAL) from patients has been proposed. To better understand the underlying mechanisms of toxicity, we propose to couple this biomonitoring of nanoparticles to their *in vitro* toxicity assessment. However, BAL obtained from regular clinical practice are conditioned with sodium hypochlorite solution (in a 50% v/v ratio), which is toxic to cells. The aim of this study was to develop a protocol to neutralize sodium hypochlorite, allowing to properly investigate the toxicity of the nanoparticles BAL contain. We first tried to neutralize chemically the sodium hypochlorite using H<sub>2</sub>O<sub>2</sub>, ascorbic acid or sodium ascorbate but this approach was unsuccessful. In addition, standard toxicology assays (MTT, LDH) could not be used because of interference with neutralizing solutions. We thus changed strategy and used ultracentrifugation to isolate nanoparticles from the sodium hypochlorite solution, with satisfactory extraction yields (88 to 100%). We then incubated the extracted nanoparticles with macrophages from the RAW264.7 cell line and assessed the cell viability and pro-inflammatory response. This study can be used as a proof-of-concept for further study of the biological impact of nanoparticles. This approach paves the way for studies aiming at a better understanding of the aetiology of some idiopathic diseases and underlying mechanisms.

Received 24th October 2023  
Accepted 29th November 2023

DOI: 10.1039/d3na00918a

rsc.li/nanoscale-advances

## 1. Introduction

Despite intensive research, the impact of inhaled engineered nanoparticles on human health is not fully elucidated yet. The biological monitoring of nanoparticles in human lung tissues or fluids represents a promising way to investigate potential causal links between an exposure to inhaled particles and biological effects and even diseases (Fig. 1).<sup>1–5</sup> This was perfectly exemplified by the correlation between the amount of asbestosis bodies in patient samples and specific lung diseases.<sup>6</sup> More recently, it has been suggested that the chemical composition of broncho-alveolar lavages from idiopathic pulmonary fibrosis patients had a specific profile that can be distinguished from that of patients with other interstitial lung diseases or healthy subjects.<sup>7</sup> We adopted this approach to detect and quantify nanoparticles in patients' biological samples such as colons,<sup>8</sup> seminal and follicular fluids,<sup>9</sup> amniotic fluids<sup>10</sup> or broncho-alveolar lavages fluids.<sup>11,12</sup> In particular,

for these latter we have evidenced a concentration of submicron silica particles higher in patients suffering from sarcoidosis than in patients suffering from other interstitial lung diseases, suggesting a potential role of these inhaled particles in the aetiology and/or development of sarcoidosis.<sup>13,14</sup>

However, this finding must be treated with caution for different reasons. First, it has to be confirmed by the analysis of a larger cohort, which is the topic of our ongoing research. And second, in-depth mechanistic studies are needed to prove a causal link with a disease, and the only presence of an inhaled particle in a larger amount within biological samples is not sufficient. Indeed, mineralogical analyses (*i.e.* biological monitoring) allow quantifying the internal dose of inhaled particles in a lung sample which differs from the external dose that can be measured by ambient monitoring (*i.e.* atmospheric metrology or surface sampling) (Fig. 1). The accumulation of biopersistent particles, reaching the biologically effective dose, can induce biological and even pathological effects.<sup>2</sup> To better characterize the continuum from exposure to disease, the identification of biomarkers is of particular interest. A biomarker has been defined as an alteration in cellular or biochemical components, processes, structures or functions which is measurable in a biological system or sample.<sup>15</sup> Three types of biomarkers have been defined: biomarkers of exposure, effect and susceptibility. In the context of occupational health,

<sup>a</sup>Mines Saint-Etienne, Univ Jean Monnet, INSERM, U 1059 Sainbiose, Centre CIS, CS 62362 42023, 158 cours Fauriel, F-42023 Saint-Etienne Cedex 2, France. E-mail: vforest@emse.fr; Tel: +33477499776

<sup>b</sup>Univ Lyon, Univ Jean Monnet, INSERM, U 1059 Sainbiose, F-42023 Saint-Etienne, France

<sup>c</sup>CHU Saint-Etienne, Service de Pneumologie, F-42055 Saint-Etienne, France






Fig. 1 Schematic view of the place and usefulness of mineralogical analyses of biological samples as biomarker of exposure and relationship with biological/pathological effects.

biomarkers can be particularly useful to support adequate assessment and management of risk with respect to nanomaterial exposure and effect.<sup>3</sup>

To better understand the toxicity potential of inhaled particles found in patients we proposed to couple the biomonitoring of particles in lung clinical samples with the *in vitro* assessment of their toxicity.<sup>16</sup> Concretely, we propose to incubate cells with particles extracted from patients' broncho-alveolar lavages and then analyse the cell response obtained in terms of induction of cell death, pro-inflammatory response, oxidative stress, *etc.*

The aim of the present proof-of-concept study is to demonstrate the feasibility of this approach. To that purpose, we first had to develop a protocol for the pre-treatment of the clinical samples. Indeed, after collection, the broncho-alveolar lavages were conditioned with sodium hypochlorite, which was added to the samples in a 50% v/v ratio. This solution has been shown to be toxic for cells<sup>17,18</sup> and *in vitro* toxicity assessments of these samples cannot be performed without first neutralizing the sodium hypochlorite. Indeed, the toxicity of the matrix should be eliminated to properly investigate the toxicity of the nanoparticles it contains. We thus developed a protocol to that purpose. We first tried to neutralize chemically the sodium hypochlorite solution using different compounds. Because this approach was unsuccessful we then isolated nanoparticles contained in broncho-alveolar lavages by ultracentrifugation. We then incubated the extracted nanoparticles with macrophages from the RAW264.7 cell line and assessed the cell response.

## 2. Results and discussion

Broncho-alveolar lavages (BAL) are routinely performed in the Chest diseases and thoracic oncology Department of the



University Hospital of Saint-Etienne. They consist of a warmed saline solution that is injected in the selected area of lung and slowly aspirated. Samples are then added with an equivalent volume of sodium hypochlorite to eliminate cells and proteins and prevent microorganism proliferation. However, for the development of our protocol of neutralisation we did not use these precious clinical samples. Instead, we reconstituted a model of BAL by mixing an equal volume of saline solution and sodium hypochlorite solution. This solution will be called "BAL-like solution" throughout the text.

### 2.1. Chemical neutralisation of sodium hypochlorite from the BAL-like solution

**2.1.1. Development of a protocol.** We aimed at developing a protocol able to manage the cytotoxic effect caused by the presence of sodium hypochlorite (NaClO) in the samples while taking care that the protocol itself did not produce toxic by-products. Different industrial dechlorination protocols exist and we focused on three of them to determine if they could be adapted to a biological context. The first protocol uses the hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) that can deplete the hypochlorite ions forming oxygen gas according to the following reaction:



The second and third protocols we assessed were based on the use of two forms of vitamin C: ascorbic acid (C<sub>6</sub>H<sub>8</sub>O<sub>6</sub>) and sodium ascorbate (C<sub>6</sub>H<sub>7</sub>O<sub>6</sub>Na) which have been shown to neutralize sodium hypochlorite as follows:



We first observed the pH variation occurring during the three neutralisation reactions.

As illustrated by Fig. 2, when  $\text{H}_2\text{O}_2$  was added to the BAL-like solution, no pH variation was observed, suggesting that either the reaction (1) did not affect the pH or it did not occur. This latter hypothesis is unlikely as the formation of bubbles was observed during the titration, sign of the production of a gas in the solution. Titration curves obtained using ascorbic acid and sodium ascorbate allowed determining equivalent volumes of 2.7 mL and 3.35 mL respectively.

**2.1.2. Validation and optimisation of the protocol.** To further investigate the efficiency of the neutralisation protocol, we compared the toxicity of neutralized samples on the RAW 264.7 macrophages to that of untreated samples. The model of macrophages appeared particularly relevant for this type of study because the role of the alveolar macrophages is to clear the lungs of inhaled particles.<sup>19</sup> First, and as illustrated by Fig. 3, cell morphology was compared by optical microscope observations when cells were exposed for 24 h either to  $\text{H}_2\text{O}_2$  ( $12 \text{ g L}^{-1}$ ), ascorbic acid ( $10 \text{ g L}^{-1}$ ), or sodium ascorbate ( $10 \text{ g L}^{-1}$ ). Cell incubation with  $\text{H}_2\text{O}_2$  clearly resulted in cell death. Exposure to ascorbic acid and ascorbate did not affect cell morphology but the appearance of crystals could be observed especially with ascorbic acid. They very likely correspond to the formation of ascorbic acid crystals.

Then the efficiency of the neutralisation protocols was evaluated with regard to cell viability and was quantified using the MTT assay, as reported by Fig. 4.

Cell viability was decreased when cells were exposed to a saline solution but it decreased to less than 10% when this saline solution was added with hypochlorite solution (*i.e.* when cells were incubated with the BAL-like solution), confirming the high cytotoxicity of hypochlorite ions. Cell viability was not

restored when BAL-like solutions were neutralized with  $\text{H}_2\text{O}_2$ , unlike what was observed when BAL-like solutions were neutralized either with ascorbic acid or sodium ascorbate. However, in the best case, cell viability was restored to only 50%, when using  $10 \text{ mg L}^{-1}$  ascorbic acid. We therefore decided to continue with this compound. To ensure the reliability of our results we performed some controls. We observed that when the BAL-like solution neutralized by  $10 \text{ mg L}^{-1}$  ascorbic acid was mixed with MTT reagent (in the absence of cells), a change of colour of the solution occurred as schematically illustrated by Fig. 5.

It suggests that our previous results could be biased because of interactions between our solutions and MTT. To better understand this phenomenon, we performed further investigations.

**2.1.3. Study on the experimental bias.** Our hypothesis was confirmed by a literature analysis. Indeed, Chakrabarti *et al.* reported that ascorbic acid could catalyse the formation of formazan<sup>20</sup> and can thus lead to false positive results when using MTT assay to determine cell viability. To get rid of this interference between ascorbic acid and MTT reagent we modified our experimental protocol. After the 24 h incubation of cells with the BAL-like solution neutralized by ascorbic acid we removed cell culture medium before adding fresh culture medium and MTT. In doing so, we avoided any contact between ascorbic acid and MTT. We observed that cell viability was almost the same when cells were incubated with the BAL-like solution or with the BAL-like solution neutralized by ascorbic acid (8% and 6.4% respectively). The restoration of cell viability previously observed was therefore not due to an efficient neutralisation of the hypochlorite solution by ascorbic acid but was rather due to a false positive signal caused by the interaction between ascorbic acid and MTT.




Fig. 2 Titration curves obtained for the neutralisation of the BAL-like solution using  $\text{H}_2\text{O}_2$  (A), ascorbic acid (B) and sodium ascorbate (C).






Fig. 3 Observation of macrophages after a 24 h exposure to  $\text{H}_2\text{O}_2$  ( $12 \text{ g L}^{-1}$ , A), ascorbic acid ( $10 \text{ g L}^{-1}$ , B) and sodium ascorbate ( $10 \text{ g L}^{-1}$ , C) by optical microscope. Arrows indicate the formation of crystals.

To confirm the inefficiency of neutralisation by ascorbic acid, we used another cytotoxicity assay: the LDH release. We observed that cytotoxicity exhibited by the cells incubated with BAL-like solution neutralized by  $10 \text{ mg L}^{-1}$  ascorbic acid was higher than that exhibited by the cells incubated with BAL-like solution (26% and 7% respectively). However, another bias could be suspected with this experiment as culture medium contained phenol red and hypochlorite solution has a bleaching power. We may thus question the impact of this phenomenon on a colorimetric assay. Indeed, we could clearly observe a change in the colour of cell culture medium when it was added with BAL-like solutions. To shed light on this issue, we performed the same experiment using a culture medium without phenol red. To compare results between the different culture conditions, the signal observed for each condition was normalised to that of cells incubated alone (negative control). As reported in Fig. 6, the same level of cytotoxicity was induced by BAL-like solution and neutralized BAL-like solution (right part of the figure). We also observed that whatever the condition tested, the cytotoxicity was lower for the experimental groups than for the control group (cells alone), suggesting that even in the absence of phenol red, this assay remains biased. And indeed, despite the transparency of the cell culture medium, a colour change was still observed when BAL-like solution was added.

Taken together these findings lead to the following conclusions: (i) standard toxicological assays such as MTT or LDH assays

based on colorimetric detection are inadequate and thus cannot be used because of interference and (ii) chemical neutralisation of hypochlorite solution by ascorbic acid is not efficient as shown by a similar cell viability when cells were incubated either with neutralized or non-neutralized BAL-like solutions.

Therefore, we changed strategy and adopted another approach consisting of eliminating physically the hypochlorite solution, *i.e.* we aimed at extracting the nanoparticles from BAL by ultracentrifugation.

## 2.2. Nanoparticle extraction from the BAL-like solution

**2.2.1. Protocol.** As before, we did not use clinical samples for the development of the protocol. We used BAL-like solutions added with a known concentration of nanoparticles ( $500 \mu\text{g mL}^{-1}$ ). We then performed an ultracentrifugation to recover the nanoparticles. As illustrated by Fig. 7, the objective here was to get a pellet containing nanoparticles and eliminate the supernatant containing the sodium hypochlorite solution. This pellet was resuspended in distilled water and its cytotoxicity was assessed. For these experiments, we selected two types of nanoparticles that we have used in previous studies (see details in the Experimental section):  $\text{CeO}_2$  and  $\text{TiO}_2$ .

**2.2.2. Determination of the extraction yield.** The quantity of Ce and Ti was determined by inductively coupled plasma





Fig. 4 Cell viability of macrophages alone (control cells) or after a 24 h incubation with the indicated conditions. Cell viability was determined by a MTT assay. Results are expressed as means of 3 independent experiments, standard deviation is also indicated. Statistical differences to control cells were determined by a one-way ANOVA analysis (\*:  $p < 0.05$ ; \*\*\*:  $p < 0.001$ ).








**Fig. 5** (A) MTT assay principle: when yellow water soluble MTT is added to cells, it is reduced into purple water insoluble formazan by mitochondrial dehydrogenases of living cells. Formazan crystals can be solubilized by solvents and the dissolved material is measured spectrophotometrically yielding absorbance as a function of the concentration of the converted dye and thus as cell viability. (B) Schematic summary of our observation: when MTT was added to BAL-like solution neutralized by ascorbic acid in the absence of the cells, the cell culture supernatant became purple while it should theoretically have remained yellow as in the absence of mitochondrial dehydrogenases the MTT should not be metabolized and formazan not produced. This observation suggests an experimental bias.

atomic emission spectroscopy (ICP-AES) either in the initial BAL-like-solution or in the pellet resuspended in distilled water. As shown by Table 1, the difference of concentration obtained before and after centrifugation allowed to calculate extraction yield for each type of nanoparticle.

The extraction yields were excellent, showing that the major, if not the entire part, of the nanoparticles was recovered after ultracentrifugation. In addition, to ensure the reliability of our results we also assessed the concentration of Ce and Ti in the supernatants. They were respectively  $0.09 \pm 0.12$  and  $0.04 \pm$



**Fig. 6** Cytotoxicity observed for cells incubated alone or after 24 h incubation with the indicated conditions and determined by the LDH release assay. Results are expressed as means of 3 independent experiments, the signal was normalised to cells alone to ease comparisons between groups, standard deviation is also indicated. Statistical differences to control cells were determined by a one-way ANOVA analysis (\*:  $p < 0.05$ ; \*\*\*:  $p < 0.001$ ).






Fig. 7 Schematic view of the nanoparticle extraction from BAL-like solution containing nanoparticles.

0.07  $\mu\text{g mL}^{-1}$ , confirming the absence of  $\text{CeO}_2$  or  $\text{TiO}_2$  nanoparticles in this fraction. Finally, to verify that most of the nanoparticles were recovered after resuspension of the pellet into distilled water, we washed the tubes three times with distilled water and analyzed the concentrations of Ce and Ti in these washes. They were found to be negligible, ranging between 0 and 6  $\mu\text{g mL}^{-1}$ .

Regarding the BAL-like solution before ultracentrifugation, it should be noted that the concentrations of Ce and Ti should have been about 500  $\mu\text{g mL}^{-1}$ . It was almost the case for Ti, but for Ce the experimentally measured value was about half the theoretical one. We thus analysed the concentrations of Ti and Ce in the nanoparticle stock solutions, they were found to be 1466.38  $\mu\text{g mL}^{-1}$  (theoretically 1600  $\mu\text{g mL}^{-1}$ ) for Ti and 2023.94  $\mu\text{g mL}^{-1}$  (instead of 4680  $\mu\text{g mL}^{-1}$ ) for Ce. This discrepancy explains why the concentration of Ce in the BAL-like solution was half the expected one.

**2.2.3. Validation.** To validate the suitability of this method, we then assessed the toxicity and pro-inflammatory response induced by the  $\text{CeO}_2$  or  $\text{TiO}_2$  nanoparticles extracted from the BAL-like solution by ultracentrifugation. For comparison, we also assessed the cytotoxicity of native  $\text{CeO}_2$  or  $\text{TiO}_2$  solutions, *i.e.* nanoparticles alone (stock solutions). All assays were performed with a nanoparticle concentration of 80  $\mu\text{g mL}^{-1}$ , a dose capable of having an impact on both cell viability and the pro-inflammatory response.<sup>21,22</sup> As reported in Fig. 8, cell viability assessed by Trypan blue exclusion assay was significantly decreased when cells were exposed to nanoparticles (either

from stock solutions or recovered from BAL-like solutions) compared to control cells. Cell viability was not statistically different between cell exposed to native nanoparticles and nanoparticles extracted from BAL-like solutions both for  $\text{CeO}_2$  and  $\text{TiO}_2$  nanoparticles. Regarding the  $\text{TNF-}\alpha$  production, it was significantly enhanced in cells incubated with nanoparticles compared to control cells. Cells exposed to nanoparticles recovered from BAL-like solution exhibited a  $\text{TNF-}\alpha$  production similar to that of cells exposed to nanoparticle stock solutions, both for  $\text{CeO}_2$  and  $\text{TiO}_2$ , although for this latter the difference was statistically significant ( $p < 0.05$ ).

Taken together, our results show that nanoparticles extracted from the BAL-like solution exhibit a toxicity profile similar to that of native nanoparticles. It suggests that we were able to restore the initial level of toxicity of nanoparticles, validating our experimental protocol and enabling us to use these solutions for toxicity assessment without any bias induced by the sodium hypochlorite conditioning solution.

## 3. Experimental

### 3.1. BAL-like solutions

For the development of the neutralisation protocol we did not use precious clinical samples, we reconstituted a model of BAL (the so-called “BAL-like solution”) by mixing an equal volume of a saline solution (0.9% w/w NaCl in distilled water) with sodium hypochlorite solution (2.6%). The solution was then filtered (0.45  $\mu\text{m}$ ).

**Table 1** Concentration of  $\text{CeO}_2$  and  $\text{TiO}_2$  nanoparticles before (BAL-like solution) and after (pellet) ultracentrifugation as determined by ICP-AES and the resulting extraction yields. Results are expressed as means of 3 independent experiments  $\pm$  standard deviation

	BAL-like solution	Pellet	Extraction yield
Concentration of Ce	200.24 $\pm$ 23.29 $\mu\text{g mL}^{-1}$	202.33 $\pm$ 13.4 $\mu\text{g mL}^{-1}$	101%
Concentration of Ti	747.12 $\pm$ 162.5 $\mu\text{g mL}^{-1}$	658.33 $\pm$ 136.35 $\mu\text{g mL}^{-1}$	88%






Fig. 8 Cytotoxicity (A) and pro-inflammatory response (B) induced by CeO<sub>2</sub> or TiO<sub>2</sub> nanoparticles extracted from the BAL-like solution by ultracentrifugation and compared to those of native CeO<sub>2</sub> or TiO<sub>2</sub> stock solutions. Results are means  $\pm$  standard deviation of 3 independent experiments. Statistical differences to control cells were determined by a one-way ANOVA analysis (\*\*\*:  $p < 0.001$ ). Statistical differences between cells incubated with nanoparticles stock solutions and cells incubated with nanoparticles extracted from the BAL-like solution were determined by a one-way ANOVA analysis (#:  $p < 0.05$ ).

### 3.2. Chemical neutralisation of the sodium hypochlorite solution

**3.2.1. Neutralisation protocols.** Hydrogen peroxide, L-ascorbic acid and sodium L-ascorbate were purchased from Sigma-Aldrich. Stock solution concentrations were 12.3 g L<sup>-1</sup>, 64 g L<sup>-1</sup> and 73.4 g L<sup>-1</sup> respectively. Final concentrations used to neutralize BAL-like solutions were 5, 10 and 16 g L<sup>-1</sup>. After addition of the different solutions to BAL-like solutions, the pH was measured (Lab Phenomenal pH 1000 L) and adjusted to a physiological pH (7–8) with hydrochloric acid (HCl 2 M, Sigma-Aldrich) or sodium hydroxide (NaOH 2 M, Sigma-Aldrich). Indeed, it has been reported that a significant loss of cell viability and cell proliferation was observed from a pH higher than 8.<sup>23</sup> However, the only adjustment of pH is not sufficient to eliminate the toxicity induced by the BAL-like solution. It is thus mandatory to neutralize the NaClO molecule. To characterize neutralisation reactions, titrations were performed by adding increasing volumes of the above-mentioned solutions to 16 mL of the BAL-like solution on a magnetic stirrer.

**3.2.2. Cell culture.** The RAW 264.7 cell line derived from mice peritoneal macrophages transformed by the Abelson murine leukaemia virus and was provided by ATCC Cell Biology Collection (Promochem, LGC). Cells were cultured in Dulbecco Modified Eagle Medium (DMEM) complemented with 10% of foetal calf serum and 1% of penicillin-streptomycin at 37 °C under a 5% carbon dioxide humidified atmosphere.

**3.2.3. MTT assay.** A MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to evaluate cell viability. Briefly, 15 000 cells per well (in a volume of 150  $\mu$ L) were seeded in 96-well-plates and were allowed to adhere overnight. Cells were exposed to BAL-like solutions (neutralized or not) and after a 24 h incubation 20  $\mu$ L of MTT (5  $\mu$ g mL<sup>-1</sup>, Sigma-Aldrich) were added in each well, and plates were incubated for 3 h at 37 °C. Then, 200  $\mu$ L of dimethylsulfoxide (DMSO, ThermoFisher Scientific) was added and thoroughly

mixed to dissolve the crystals. The optical density of each sample was determined using a microplate reader (Multiskan RC, Thermolabsystems) set to 570 nm. Negative and positive controls were included: cells incubated alone and cells incubated in the presence of 0.1% Triton X-100 (Sigma-Aldrich).

For the bias study, cell culture supernatant was removed by aspiration before the addition of 200  $\mu$ L of fresh culture medium and 20  $\mu$ L of MTT. The other steps of the protocol remained unchanged.

**3.2.4. LDH assay.** 25 000 cells per well (in a volume of 150  $\mu$ L) were seeded in 96-well-plates and were allowed to adhere overnight. Cells were exposed to BAL-like solutions (neutralized or not) and after a 24 h incubation cell membrane integrity was evaluated. The cellular release in the supernatant of cytoplasmic lactate dehydrogenase (LDH) was assessed using the CytoTox-96™ Homogeneous Membrane Integrity Assay (Promega) according to the manufacturer's instructions. The optical density of the samples was determined using a microplate reader (Multiskan RC, Thermolabsystems) set to 490 nm. Three independent experiments were performed, each in quadruplicate and the activity of the released LDH was reported to that of negative control cells (cells alone). A positive control consisting of the maximal cellular LDH released after cells lysis was used.

To determine potential colorimetric bias, experiments were performed in different media: either DMEM containing phenol red (Sigma-Aldrich) or DMEM without phenol red (Pan-Biotech).

### 3.3. Nanoparticles extraction by ultracentrifugation

As before, we did not use clinical samples for the development of the protocol. We used BAL-like samples added with a known amount of nanoparticles.

**3.3.1. Nanoparticles.** Two types of nanoparticles were used: cerium oxide (CeO<sub>2</sub>) and titanium dioxide (TiO<sub>2</sub>) nanoparticles, they came from our sample collection in the laboratory. We already performed physico-chemical characterization and *in*



*vitro* toxicity analyses.<sup>21,22</sup> CeO<sub>2</sub> particles were rod-shaped, their size was about 8 × 70 nm, they exhibited a specific surface area of 37 m<sup>2</sup> g<sup>-1</sup>, a zeta potential of -31 mV, their agglomeration/aggregation state was low, they were previously found to trigger a high toxicity level on RAW264.7 macrophages.<sup>21</sup> TiO<sub>2</sub> nanoparticles were spherical nanoparticles which size was about 15 nm in diameter, with a surface specific area of 146 m<sup>2</sup> g<sup>-1</sup>, a zeta potential of -13 mV, the crystalline phase was anatase, their agglomeration/aggregation state was low.<sup>22</sup> Before use, TiO<sub>2</sub> nanoparticle solution (1.6 g L<sup>-1</sup>) and CeO<sub>2</sub> nanoparticle solution (4.68 g L<sup>-1</sup>) were sonicated (Branson S-450) for 15 min and vortexed (TopMix Vortex Shaker) for 2 min to ensure an homogeneous dispersion of the particles. To reach a nanoparticle final concentration of 0.5 mg mL<sup>-1</sup>, 0.45 mL of TiO<sub>2</sub> nanoparticle solution was added to 3.75 mL of BAL-like solution and 1.3 mL of CeO<sub>2</sub> nanoparticle solution were added to 2.9 mL of BAL-like solution.

**3.3.2. Ultracentrifugation.** Tubes were sealed and placed in the JS-24.15 rotor (Beckman Coulter) of the Avanti J-30I ultracentrifuge (Beckman Coulter). Centrifugation lasted for 30 min at 20 000 rpm, at room temperature. Supernatant was recovered and transferred into a new tube, the pellet was resuspended into 4.2 mL of distilled water and transferred into a new tube. The particle concentration in these two fractions was determined by ICP-AES.

**3.3.3. ICP-AES analyses.** The concentration of Ce or Ti was determined by inductively coupled plasma atomic emission spectroscopy (ICP-AES, Ultratrace JY-138, Jobin-Yvon) in BAL-like solution (before ultracentrifugation), in the supernatant and in the pellet resuspended in distilled water. 500 µL of each sample was added with 9.5 mL of PBS. To evaluate the background noise, BAL-like solutions without nanoparticles were also analysed. Results were expressed as means of three independent experiments and were expressed as parts-per-million (ppm), *i.e.* µg mL<sup>-1</sup>. Extraction yields were determined by calculating the difference of solution concentration before and after centrifugation.

**3.3.4. Cell viability assessed by Trypan blue exclusion assay.** RAW264.7 cells were seeded in 6 well-plates (1.5 million cells per well in a volume of 2 mL). Cells were allowed to adhere overnight. Culture medium was removed and replaced by fresh culture medium containing 80 µg mL<sup>-1</sup> CeO<sub>2</sub> or TiO<sub>2</sub> nanoparticles either extracted from BAL-like solution (pellet) or from stock solutions. After a 24 h incubation at 37 °C, the cell morphology was observed under a microscope. Cells were detached from the wells using a cell scraper and cell suspensions were transferred in new tubes. 80 µL of Trypan Blue diluted 1/5 were added to 20 µL of the cell suspension previously homogenized. Living and dead cells were counted using a Thoma counting chamber. Cell viability was calculated as the ratio between living cells and total cells (dead + living) and was expressed as a percentage. Three independent experiments were performed, each in triplicate.

**3.3.5. TNF-α assay.** 100 000 cells (in a volume of 150 µL) were seeded per well in 96-well-plates and were allowed to adhere overnight. Cells were exposed for 24 h to the previously mentioned solutions. The production of TNF-α was assessed in

the cell culture supernatant using a commercial ELISA kit (Quantikine® Mouse TNF-α Immunoassay, R&D Systems) according to the manufacturer's instructions. The optical density of each sample was determined using a microplate reader (Multiskan RC, Thermolabsystems) set to 450 nm. A standard curve was established and results were expressed in picograms of TNF-α per millilitre of supernatant. Three independent experiments were performed, each in duplicate and the production of TNF-α was reported to that of control cells (cells alone).

### 3.4. Statistical analyses

Results are expressed as means of 3 independent experiments where endpoints were assessed in quadruplicates unless otherwise stated. One-way ANOVA analyses were performed to determine statistical differences (*p* < 0.05) between experimental and control groups or between experimental groups.

## 4. Conclusions

The chemical neutralisation of sodium hypochlorite solution was found to be ineffective. In addition, standard toxicology assays could not be used because of interferences with sodium hypochlorite neutralizing solution. On the contrary, using ultracentrifugation was found to be an efficient approach to isolate nanoparticles from the sodium hypochlorite solution, with excellent extraction yields. This study can therefore be used as a proof-of-concept for further toxicological assays in biological samples containing sodium hypochlorite solution. It opens new perspectives for the study of the biological impact of nanoparticles. This approach paves the way for studies aiming at a better understanding of the aetiology of some idiopathic diseases and underlying mechanisms.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

The authors would like to acknowledge Juan Felipe Porras Yaruro and Karla Mirallès for their participation to the experiments as part of their research project.

## References

- 1 J. D. Groopman and T. W. Kensler, *Carcinogenesis*, 1999, **20**, 1–11.
- 2 J. Angerer, U. Ewers and M. Wilhelm, *Int. J. Hyg. Environ. Health*, 2007, **210**, 201–228.
- 3 I. Iavicoli, V. Leso, M. Manno and P. A. Schulte, *J. Nanopart. Res.*, 2014, **16**, 2302.
- 4 M. Rinaldo, P. Andujar, A. Lacourt, L. Martinon, M. Canal Raffin, P. Dumortier, J.-C. Pairon and P. Brochard, *Ann. Occup. Hyg.*, 2015, **59**, 669–680.
- 5 E. Bergamaschi, *J. Nanomater.*, 2012, **2012**, 564121.





- 6 P. De Vuyst, A. Karjalainen, P. Dumortier, J. C. Pairon, E. Monsó, P. Brochard, H. Teschler, A. Tossavainen and A. Gibbs, *Eur. Respir. J.*, 1998, **11**, 1416–1426.
- 7 E. Bargagli, F. Lavorini, M. Pistolesi, E. Rosi, A. Prasse, E. Rota and L. Voltolini, *J. Trace Elem. Med. Biol.*, 2017, **42**, 39–44.
- 8 L. Rinaldi, G. Barabino, J.-P. Klein, D. Bitounis, J. Pourchez, V. Forest, D. Boudard, L. Leclerc, G. Sarry, X. Roblin, M. Cottier and J.-M. Phelip, *Dig. Liver Dis.*, 2015, **47**, 602–607.
- 9 D. Bitounis, J.-P. Klein, L. Mery, A. El-Merhie, V. Forest, D. Boudard, J. Pourchez and M. Cottier, *Anal.*, 2018, **143**, 475–486.
- 10 T. Raia-Barjat, C. Prieux, L. Leclerc, G. Sarry, L. Grimal, C. Chauleur, J. Pourchez and V. Forest, *J. Trace Elem. Med. Biol.*, 2020, **60**, 126477.
- 11 V. Forest, J.-M. Vergnon, C. Guibert, D. Bitounis, L. Leclerc, G. Sarry and J. Pourchez, *Nanotoxicology*, 2017, **11**, 1211–1224.
- 12 D. Bitounis, V. Barnier, C. Guibert, J. Pourchez, V. Forest, D. Boudard, J.-F. Hochepped, P. Chelle, J.-M. Vergnon and M. Cottier, *Nanoscale*, 2018, **10**, 2955–2969.
- 13 V. Forest, J. Pourchez, C. Guibert, D. Bitounis, L. Leclerc, G. Sarry and J.-M. Vergnon, *Environ. Sci.: Nano*, 2019, **6**, 1343–1350.
- 14 V. Forest, J. Pourchez, C. Pélissier, S. Audignon Durand, J.-M. Vergnon and L. Fontana, *Toxics*, 2021, **9**, 204.
- 15 M. Manno, C. Viau, J. Cocker, C. Colosio, L. Lowry, A. Mutti, M. Nordberg and S. Wang, *Toxicol. Lett.*, 2010, **192**, 3–16.
- 16 V. Forest, J.-M. Vergnon and J. Pourchez, *Chem. Res. Toxicol.*, 2017, **30**, 1655–1660.
- 17 T. Vouzara, E. Koulaouzidou, F. Ziouti and N. Economides, *Int. Endod. J.*, 2016, **49**, 764–773.
- 18 A.-L. Severing, J.-D. Rembe, V. Koester and E. K. Stuermer, *J. Antimicrob. Chemother.*, 2019, **74**, 365–372.
- 19 R. F. Hamilton, S. A. Thakur and A. Holian, *Free Radical Biol. Med.*, 2008, **44**, 1246–1258.
- 20 R. Chakrabarti, S. Kundu, S. Kumar and R. Chakrabarti, *J. Cell. Biochem.*, 2000, **80**, 133–138.
- 21 V. Forest, L. Leclerc, J.-F. Hochepped, A. Trouvé, G. Sarry and J. Pourchez, *Toxicol. In Vitro*, 2017, **38**, 136–141.
- 22 O. Kose, M. Tomatis, L. Leclerc, N.-B. Belblidia, J.-F. Hochepped, F. Turci, J. Pourchez and V. Forest, *Chem. Res. Toxicol.*, 2020, **33**, 2324–2337.
- 23 C. G. Mackenzie, J. B. Mackenzie and P. Beck, *J. Biophys. Biochem. Cytol.*, 1961, **9**, 141–156.

